Showing results (31-40 of 96) with videos related to
Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2011
Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75Noah M Hahn, Walter M Stadler, Robin T Zon, et al.Diseases of the Colon and Rectum|August 7, 2008
Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot studyDavid W Dietz, Farrokh Dehdashti, Perry W Grigsby, et al.Cancer Chemotherapy and Pharmacology|July 4, 2013
A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancerDana E Rathkopf, Joel Picus, Arif Hussain, et al.Cancer|July 25, 2003
Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignanciesPaula M Fracasso, Luis C Rodriguez, Thomas J Herzog, et al.HPB : the Official Journal of the International Hepato Pancreato Biliary Association|March 25, 2015
A phase II study of adjuvant gemcitabine plus docetaxel followed by concurrent chemoradation in resected pancreaticobiliary carcinomaMay Cho, Andrea Wang-Gillam, Robert Myerson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206Brian I Rini, Susan Halabi, Jonathan E Rosenberg, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2003
Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663Mary-Ellen Taplin, Barur Rajeshkumar, Susan Halabi, et al.Molecular Imaging and Biology|November 15, 2015
Phase 1 Evaluation of [(64)Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid TumorsA Craig Lockhart, Yongjian Liu, Farrokh Dehdashti, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2019
Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate CancerSusan Slovin, Syed Hussain, Fred Saad, et al.Investigational New Drugs|March 19, 2021
Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I studyKatrina S Pedersen, Patrick M Grierson, Joel Picus, et al.Pageof 10